Kura Oncology, Inc. (KURA)
| Market Cap | 569.32M |
| Revenue (ttm) | 53.88M |
| Net Income (ttm) | -173.98M |
| Shares Out | 80.75M |
| EPS (ttm) | -2.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 582,102 |
| Open | 7.14 |
| Previous Close | 7.14 |
| Day's Range | 6.96 - 7.22 |
| 52-Week Range | 6.79 - 23.48 |
| Beta | 0.84 |
| Analysts | Strong Buy |
| Price Target | 25.50 (+261.7%) |
| Earnings Date | May 1, 2025 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for pa... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price forecast is $25.5, which is an increase of 261.70% from the latest price.
News
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines f...
Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity
Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations throu...
Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP...
Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results
– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpo...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines fo...
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines fo...
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology, Inc. KURA and Kyowa Kirin Co., Ltd released topline results from a Phase 2 registration-directed trial of ziftomenib for relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leu...
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting –
Kura Oncology Announces Senior Executive Promotions
– Mollie Leoni, M.D. promoted to Chief Medical Officer – – Francis Burrows, Ph.D.
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Zift...
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –
Kura Oncology to Host Virtual Investor Event on December 9, 2024
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data ...
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Do...
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –
Kura Oncology to Report Third Quarter 2024 Financial Results
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the ap...
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models –
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
– New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics – – New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Target...
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Pete De Spain - Head, IR Troy Wilson - President and CEO Thomas Doyle - SVP of Financ...